Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.57%
#2 Movement Movement +6.40%
#3 Palladium Network Palladium Network +5.02%
#4 Prom Prom +4.17%
#5 GRVT Token GRVT Token +3.87%
#6 Cryptopia Cryptopia +3.74%
#7 SIXSEVEN SIXSEVEN +3.67%
#8 Test Test +3.60%
#9 Kinetiq Kinetiq +3.58%
#10 Jito Jito +3.53%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Arno Therapeutics, Inc. Arno Therapeutics, Inc.

Arno Therapeutics, Inc.

ARNI
Classifica tra le azioni #42094
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a... Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
Prezzo delle azioni
$0.0001
Ultima sincronizzazione: 2026-08-11
Capitalizzazione di mercato
$4.94K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Arno Therapeutics, Inc. (ARNI)

Categoria

Healthcare
Ricavi di Arno Therapeutics, Inc. (ARNI)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Arno Therapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Arno Therapeutics, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR